Summary & Overview
HCPCS J7314: Fluocinolone Acetonide Intravitreal Implant (Yutiq) 0.01 mg
HCPCS Level II code J7314 denotes the intravitreal implant injection of fluocinolone acetonide (Yutiq), 0.01 mg, a sustained-release corticosteroid placed directly into the vitreous cavity for long-term intraocular inflammation control. This code matters nationally because it captures utilization and billing for a specialty ophthalmic drug-procedure combination that has implications for outpatient ophthalmology practice patterns, payer coverage policies, and drug spend for sight-threatening inflammatory eye diseases.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of the implant, typical sites of service where the procedure is performed, and coding specifics tied to billing the intravitreal implant. The publication outlines payer coverage considerations, common billing modifiers, and benchmarking subjects relevant to facilities and clinicians who perform intravitreal drug implantation.
The piece also summarizes typical reimbursement and claim-line considerations, notes on billing workflow for an implanted ophthalmic drug, and areas where policy updates or prior authorization requirements often influence access. Data not available in the input will be identified clearly in relevant sections.
Billing Code Overview
HCPCS Level II code J7314 represents an intravitreal implant injection of fluocinolone acetonide (Yutiq), 0.01 mg. This service is a drug administration of a sustained-release corticosteroid implant delivered directly into the vitreous cavity of the eye.
Service Type: Intravitreal drug administration / ophthalmic implant
Typical Site of Service: Ophthalmology clinic, ambulatory surgery center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of chronic noninfectious uveitis of the posterior segment presents for intravitreal therapy after recurrent inflammation despite systemic immunosuppression. The ophthalmologist determines that a sustained-release intravitreal corticosteroid implant is appropriate to reduce intraocular inflammation and preserve vision. The procedure performed is insertion of a 0.01 mg fluocinolone acetonide intravitreal implant (J7314/YUTIQ) in a procedure suite or ambulatory surgery center under local anesthesia with sterile technique. Pre-procedure workflow includes informed consent, medication reconciliation, baseline visual acuity and intraocular pressure measurements, topical antisepsis, and topical or local anesthetic administration. The implant is delivered via a preloaded applicator through a pars plana entry; post-procedure steps include intraocular pressure monitoring, topical antibiotic drop administration, patient instructions for signs of infection or elevated pressure, and scheduling of follow-up visits at 1 day, 1 week, and periodic intervals to monitor efficacy and adverse effects. Typical site of service is an ophthalmology clinic procedure room, ambulatory surgery center, or outpatient hospital setting. Common payors covering this implant include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Original submission |